Product Details
| Product Name:
VULM 1457 |
CAS No.:
228544-65-8 |
| Purity:
99.92% |
Supply Ability:
10g |
| Release date:
2024/11/19 |
Product Introduction
Bioactivity
| Name | VULM 1457 |
| Description | VULM 1457 is a potent ACAT inhibitor. VULM 1457 has remarkable hypolipidaemic activity and improves the overall myocardial ischaemia-reperfusion injury outcomes. VULM1457 significantly reduces production and secretion of adrenomedullin (AM) and down-regulates AM receptors on human hepatoblastic cells. |
| In vitro | Preincubation of HepG2 cells with VULM1457 (0.1 μM) significantly reduced the specific [125I]AM binding on hypoxic cells with BmaxHypox being 127±10 and KD 0.06±0.11 nM. Preincubation of cells with VULM1457 (0.1 μM) significantly enhanced the number of cells (24.2±6 %) and higher concentrations of VULM1457 (1.0 and 10.0 μM) reduces the total number of cells[2]. In HepG2 cell lines, VULM1457 (0.03 μM; 0.1 μM) significantly down-regulated specific AM receptors on HepG2 cells, and reduced AM secretion of HepG2 cells exposed to hypoxia. VULM1457 negatively regulates cell proliferation induced by AM[2]. |
| In vivo | In male Wistar rats, VULM 1457 protected the hearts of diabetic–hypercholesterolaemic rats against ischemia/reperfusion injury in vivo[1]. VULM 1457 (50 mg/kg/day) significantly decreases plasma total cholesterol levels (1.7±0.1 mM vs. 2.9±0.5 mM in diabetic–hypercholesterolaemic animals). The hypolipidaemic effect of VULM 1457 is also observed in the liver of DM-HCH rats (3.9±0.2 mg/g vs. 7.4±1.0 mg/g)[1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 60 mg/mL (133.46 mM)
|
| Keywords | acyl-CoA:cholesterol acyltransferase | hypercholesterolaemia | VULM 1457 | Diacylglycerol acyltransferase | ischaemia-reperfusion | myocardial | Diglyceride acyltransferase | mono- acylglycerol acyltransferase | Inhibitor | acyl-CoA | VULM-1457 | cholesterol acyltransferase | Acyltransferase | VULM1457 | hypolipidaemic | inhibit | diabetes mellitus |
| Inhibitors Related | Xanthohumol | Lecimibide | Avasimibe | Cyclandelate | Eldacimibe | YM17E | 2-Furoic acid | Eflucimibe | Monatepil 2maleate | A 922500 | TMP-153 | PF-04620110 |
| Related Compound Libraries | Bioactive Compound Library | Inhibitor Library | Metabolism Compound Library | Bioactive Compounds Library Max |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
CAS:165383-72-2
$59.00 / 1mg
-
CAS:1395048-49-3
$58.00 / 5mg
-
CAS:28315-93-7
$61.00 / 500mg
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
$1520.00/25mg |
VIP1Y
|
TargetMol Chemicals Inc.
|
2024-10-23 |
|
|
$99.00/1EA |
|
Amikon Limited
|
2018-09-07 |
United States